A United States-based retrospective cohort demonstrated that abnormal liver tests were commonly observed in hospitalized patients with COVID-19, both on admission (AST 66.9%, ALT 41.6%, ALP 13.5%, and TBIL 4.3%) and peak hospitalization (AST 83.4%, ALT 61.6%, ALP 22.7%, and TBIL 16.1%) and also during recovery. The gene discussed is GPT; the disease is COVID-19.